“After a challenging period for Healthcare returns, valuations across the sector have become increasingly attractive. At the index level, the ASX 100 Healthcare sector now trades at two-decade lows on a relative P\/E basis.”<\/p>\n
Here are two ASX healthcare shares with big upside according to brokers.\u00a0<\/p>\n
![\"Three](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/03\/three-medics-1200x675.jpg\")
<\/p>\n
Image source: Getty Images<\/p>\n
Anteris Technologies Global Corp (ASX: AVR<\/a>) <\/p>\n Anteris Technologies is a structural heart company. It researches, develops, commercialises, and distributes various medical technologies<\/a> and devices.\u00a0<\/p>\n It manufactures, distributes, and sells ADAPT & DurAVR regenerative tissue products, and researches and develops regenerative medicine and immunotherapies.<\/p>\n This ASX healthcare stock is down more than 19% over the last 12 months, but has begun to recover from yearly lows.\u00a0<\/p>\n Recently, Bell Potter<\/a> raised its price target to $13 (from $10), along with retaining a speculative buy rating.\u00a0 <\/p>\n The broker has optimism around its future thanks to progress in getting its DurAVR product <\/a>approved.\u00a0<\/p>\n The product uses a single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve.<\/p>\n Based on yesterday’s closing price of $8.86, this Bell Potter price target indicates potential upside of almost 47%.\u00a0<\/p>\n Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) <\/p>\n Another ASX healthcare stock tipped to recover is Telix Pharmaceuticals.\u00a0<\/p>\n It is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation. <\/p>\n Its share price has fallen almost 60% over the last year; however, experts are anticipating a bounce back.\u00a0<\/p>\n